Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 27 TH ANNUAL HEALTHCARE CONFERENCE Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SU...

Trends and Targets for 6/03/2017

FTSE FOR THE WEEK (FTSE:UKX) Friday was irritating. It's one thing to speculate "all the action will happen at the open...

Summit Therapeutics Recognises Tenth Annual Rare Disease Day

Summit Therapeutics Recognises Tenth Annual Rare Disease Day Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT THERAPEUTICS RECOGNISES 10 TH ANNUAL RARE DISEASE DAY Oxford, UK, 28 February 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies f...

Summit Therapeutics plc : Exercise of Warrants

Summit Therapeutics plc: Exercise of Warrants Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

All News

DateHeadlineSource
15-03-17Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceRNS
05-03-17Trends and Targets for 6/03/2017Trends and Targets
28-02-17Summit Therapeutics Recognises Tenth Annual Rare Disease DayRNS
23-02-17Summit Therapeutics plc : Exercise of WarrantsRNS
02-02-17Summit to take part in investor conferencesStockMarketWire
02-02-17Summit Therapeutics to Participate in February Investor ConferencesRNS
01-02-17Summit outlines Phase 3 programme for ridinilazoleStockMarketWire
01-02-17Summit Outline Phase 3 Programme for Novel CDI Antibiotic RidinilazoleRNS
25-01-17Summit Therapeutics plc : Holding(s) in CompanyRNS
19-01-17Summit Therapeutics plc : Exercise of OptionsRNS
18-01-17Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentRNS
15-12-16Summit Therapeutics plc : 3rd Quarter ResultsRNS
13-12-16Summit Therapeutics plc : Notice of ResultsRNS
16-11-16Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS
24-10-16Summit Therapeutics plc : Exercise of OptionsRNS
19-10-16Summit Therapeutics plc : Holding(s) in CompanyRNS
14-10-16Summit Therapeutics plc : Exercise of OptionsRNS
11-10-16Summit Therapeutics plc : Exercise of OptionsRNS
07-10-16Summit Therapeutics plc : Exercise of OptionsRNS
06-10-16Summit Presents Preclinical DMD Data at 21st Congress of World Muscle SocietyRNS
04-10-16FTSE closes close to its record high StockMarketWire
04-10-16Why Summit Therapeutics just doubledInteractive Investor
04-10-16Summit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash GuidanceRNS
04-10-16Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with SareptaRNS
04-10-16Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration AgreementRNS
28-09-16Summit Therapeutics plc : Holding(s) in CompanyRNS
27-09-16Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMDRNS
26-09-16Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMDRNS
08-09-16Summit Therapeutics widens H1 lossStockMarketWire
08-09-16Summit Therapeutics plc : Half-yearly reportRNS
07-09-16Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceRNS
05-09-16Summit Therapeutics plc : Notice of ResultsRNS
09-08-16Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate EzutromidRNS
05-08-16Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceRNS
18-07-16Summit Therapeutics plc : Result of AGMRNS
28-06-16Summit Therapeutics plc : Exercise of OptionsRNS
24-06-16Summit Therapeutics plc : Award of OptionsRNS
21-06-16Summit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionRNS
17-06-16Summit Therapeutics plc : Notice of AGMRNS
17-06-16First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMDRNS

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory